Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
- Registration Number
- NCT00522834
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Brief Summary
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals.
Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone.
One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. "
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 630
- Histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin
- ECOG performance status of <=2
- Measurable disease according to modified RECIST
- Life expectancy of greater than 12 weeks
- LDH <= 2.0 x ULN
- Clinical lab values within protocol parameters.
- At least 18 years old and able and willing to provide informed consent to participate
- Previous cytotoxic chemotherapy treatment for melanoma
- Received more than one regimen of immunotherapy, kinase inhibitor, biologic therapy, vaccine or investigational non-chemotherapeutic treatment for melanoma.
- Presence of brain metastases
- Presence or history (<= 5 years) of a second malignancy other than nonmelanoma skin cancer or cervical carcinoma in situ
- Female subjects who are pregnant or nursing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Elesclomol (STA-4783) Elesclomol (STA-4783) in Combination With Paclitaxel 2 Paclitaxel Paclitaxel alone
- Primary Outcome Measures
Name Time Method Progression free survival June 2009
- Secondary Outcome Measures
Name Time Method Overall Survival December 2009 Clinical benefit rate December 2009 Safety December 2009 Pharmacokinetics December 2009 Objective response rate December 2009 Duration of objective response December 2009
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (99)
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
Winthrop P. Rockefeller Cancer Institute
🇺🇸Little Rock, Arkansas, United States
University of California San Diego Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
University of California, San Diego
🇺🇸La Jolla, California, United States
The Angeles Clinic & Research Institute
🇺🇸Los Angeles, California, United States
Jonsson Comprehensive Cancer Center Univ. of California Los Angeles
🇺🇸Los Angeles, California, United States
Pacific Medical Center Research Institute
🇺🇸San Francisco, California, United States
Redwood Regional Medical Group
🇺🇸Santa Rosa, California, United States
Anschutz Cancer Pavillion University of Colorado
🇺🇸Aurora, Colorado, United States
Hematology Oncology, P.C.
🇺🇸Stamford, Connecticut, United States
Scroll for more (89 remaining)Arizona Cancer Center🇺🇸Tucson, Arizona, United States